Vera Therapeutics/$VERA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Vera Therapeutics
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
- Ticker
- $VERA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 361
- Headquarters
- Brisbane, United States
- Website
- veratx.com
VERA Metrics
BasicAdvanced
$2.2B
-
-$5.89
0.95
-
Price and volume
Market cap
$2.2B
Beta
0.95
52-week high
$56.05
52-week low
$23.05
Average daily volume
1.7M
Financial strength
Current ratio
10.916
Quick ratio
10.411
Long term debt to equity
0.189
Total debt to equity
0.189
Interest coverage (TTM)
-55.18%
Profitability
EBITDA (TTM)
-415.224
Effective tax rate (TTM)
-0.00%
Management effectiveness
Return on assets (TTM)
-46.76%
Return on equity (TTM)
-91.75%
Valuation
Price to book
5.46
Price to tangible book (TTM)
5.47
Price to free cash flow (TTM)
-6.229
Free cash flow yield (TTM)
-16.05%
Free cash flow per share (TTM)
-4.973
Growth
Earnings per share change (TTM)
64.06%
3-year earnings per share growth (CAGR)
23.41%
What the Analysts think about VERA
Analyst ratings (Buy, Hold, Sell) for Vera Therapeutics stock.
Analyst projections of the future price of Vera Therapeutics stock.
Bulls say / Bears say
ORIGIN 3’s final analysis showed kidney function was nearly stable at 52 weeks, while kidney-disease progression events fell 76% versus placebo over 104 weeks. This gives TRUTAKNA unusually strong evidence of clinical benefit beyond reducing protein in urine. (Vera Therapeutics)
The FDA granted TRUTAKNA accelerated approval in July, making Vera a commercial-stage company and giving it a route to sell its dual BAFF/APRIL treatment to eligible IgAN patients. (GlobeNewswire)
Vera reported more than 350 patient start forms in TRUTAKNA’s first ten weeks on the market. That is an early sign of physician and patient interest as the company builds its first commercial franchise. (Vera Therapeutics)
IgAN is a crowded market, and Vertex’s competing dual BAFF/APRIL drug has reported similar proteinuria results and faces an FDA decision in November. That could narrow Vera’s first-mover advantage and limit its eventual market share. (Fierce Pharma)
Vera’s commercial ramp is still unproven, while recent commentary flags continued losses and rising cash burn. If patient uptake is slower than hoped, financing needs could increase before sales support the business. (TipRanks)
TRUTAKNA still has accelerated, rather than full, FDA approval. Vera plans to submit confirmatory kidney-function data in a supplemental application in Q4 2026, so regulatory review and the timing of full approval remain risks despite the positive trial results. (Vera Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.
VERA Financial Performance
Revenues and expenses
VERA Earnings Performance
Company profitability
Upcoming events
No upcoming events
VERA News
AllArticlesVideos
Funds containing VERA
Fund name | Fund size | $VERA weighting |
|---|---|---|
Xtrackers S&P 500 Swap£XSPX | $9.7B | 0.24% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.14% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.14% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.07% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.07% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.